Table 3 Risk ratio (RR) of progression according to each biomarker
Marker | Progression | No progression | Total | ||
|---|---|---|---|---|---|
≤ 3 months | ≤ 6 months | Anytime after marker appearance | |||
ESR1 mutation | |||||
n (%) | 10 (56%) | 14 (78%) | 18 (100%) | 0 (0%) | 18 (100%) |
RR (ref = non mut) | 4.9 [3.0–8.0] | 3.3 [2.4–4.5] | 1.9 [1.7–2.0] | – | |
> 25% CA-15.3 increase | |||||
n (%) | 12 (60%) | 14 (70%) | 18 (90%) | 2 (10%) | 20 (100%) |
RR (ref = no increase) | 5.9 [3.8–9.2] | 3.4 [2.5–4.8] | 2.0 [1.7–2.4] | – | |
> 100% CA-15.3 increase | |||||
n (%) | 2 (50%) | 2 (50%) | 2 (50%) | 2 (50%) | 4 (100%) |
RR (ref = no increase) | 4.0 [1.5–11.0] | 2.2 [0.8–5.8] | 1.1 [0.4–2.8] | – | |
> 25% DNA increase | |||||
n (%) | 14 (18%) | 22 (29%) | 45 (58%) | 32 (42%) | 77 (100%) |
RR (ref = no increase) | 1.6 [0.8–3.3] | 1.1 [0.7–1.7] | 0.9 [0.7–1.2] | – | |
> 100% DNA increase | |||||
n (%) | 8 (19%) | 13 (31%) | 20 (48%) | 22 (52%) | 42 (100%) |
RR (ref = no increase) | 1.4 [0.7–2.7] | 1.1 [0.6–1.7] | 0.8 [0.6–1.2] | – | |